JP2016528162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528162A5 JP2016528162A5 JP2015562231A JP2015562231A JP2016528162A5 JP 2016528162 A5 JP2016528162 A5 JP 2016528162A5 JP 2015562231 A JP2015562231 A JP 2015562231A JP 2015562231 A JP2015562231 A JP 2015562231A JP 2016528162 A5 JP2016528162 A5 JP 2016528162A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- lenvatinib
- eribulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 25
- 201000011510 cancer Diseases 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 15
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims 15
- 229960003649 eribulin Drugs 0.000 claims 13
- 229960003784 lenvatinib Drugs 0.000 claims 13
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 229960000439 eribulin mesylate Drugs 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 229960001429 lenvatinib mesylate Drugs 0.000 claims 2
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839542P | 2013-06-26 | 2013-06-26 | |
| US61/839,542 | 2013-06-26 | ||
| PCT/JP2014/067723 WO2014208774A1 (en) | 2013-06-26 | 2014-06-26 | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528162A JP2016528162A (ja) | 2016-09-15 |
| JP2016528162A5 true JP2016528162A5 (cg-RX-API-DMAC7.html) | 2017-08-03 |
| JP6404242B2 JP6404242B2 (ja) | 2018-10-10 |
Family
ID=51210708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562231A Active JP6404242B2 (ja) | 2013-06-26 | 2014-06-26 | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9549922B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3013335B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6404242B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102265952B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105338977B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014299699B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015029386B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2915005C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2705698T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL242386B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2672585C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014208774A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2415470T (pt) | 2009-03-30 | 2016-08-31 | Eisai R&D Man Co Ltd | Composição de lipossomas |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| SMT202200367T1 (it) | 2014-08-28 | 2022-11-18 | Eisai R&D Man Co Ltd | Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso |
| CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| BR112017018872A2 (pt) * | 2015-03-04 | 2018-05-29 | Eisai R&D Man Co Ltd | combinação de um antagonista pd-1 e eribulina para tratamento de câncer |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
| AU2016309356B2 (en) | 2015-08-20 | 2021-06-24 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| EP3449921B1 (en) * | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| CN105832732A (zh) * | 2016-05-30 | 2016-08-10 | 青岛云天生物技术有限公司 | 一种用于胃癌治疗的药物组合物及其应用 |
| WO2018124847A1 (ko) * | 2017-01-02 | 2018-07-05 | 연성정밀화학(주) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 |
| ES2971448T3 (es) * | 2017-02-08 | 2024-06-05 | Eisai R&D Man Co Ltd | Composición farmacéutica para el tratamiento de tumores |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN107973804B (zh) * | 2017-11-29 | 2020-07-03 | 戊言医药科技（上海）有限公司 | 艾瑞布林中间体的合成方法 |
| KR20250073570A (ko) * | 2018-01-10 | 2025-05-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간세포성 암종의 치료를 위한 조합 요법 |
| CN109793736A (zh) * | 2019-01-31 | 2019-05-24 | 徐州医科大学 | 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用 |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN114028394A (zh) * | 2021-05-21 | 2022-02-11 | 中山大学 | 低剂量仑伐替尼在制备治疗肝癌的药物中的用途 |
| JP2024531220A (ja) * | 2021-08-10 | 2024-08-29 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｔｉｇｉｔアンタゴニスト、ｐｄ－１アンタゴニスト、及びレンバチニブを含む治療薬の組み合わせ |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| AU762998B2 (en) | 1998-06-17 | 2003-07-10 | Eisai R&D Management Co., Ltd. | Macrocyclic analogs and methods of their use and preparation |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| AU2003211594A1 (en) | 2002-03-05 | 2003-09-16 | Eisai Co., Ltd. | Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor |
| WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| SI1698623T1 (sl) | 2003-12-25 | 2015-07-31 | Eisai R&D Management Co., Ltd. | Kristal soli 4-(3-kloro -4-(ciklopropilaminokarbonil)amino-fenoksi)-7- metoksi-6-kinolinkarboksamida ali njihov solvat in postopek njune proizvodnje |
| JP5226304B2 (ja) * | 2004-06-03 | 2013-07-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンｂ類似体の調製用中間体 |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US20090053236A1 (en) | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| WO2008088088A1 (ja) | 2007-01-19 | 2008-07-24 | Eisai R & D Management Co., Ltd. | 膵癌治療用組成物 |
| EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| KR101573026B1 (ko) * | 2007-07-25 | 2015-11-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암 치료에서 이용하기 위한 멀티키나아제 억제제 |
| SG10201811715YA (en) | 2007-10-03 | 2019-02-27 | Eisai R&D Man Co Ltd | Intermediates and methods for the synthesis of halichondrin b analogs |
| WO2009060945A1 (ja) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
| EP2248804A4 (en) | 2008-01-29 | 2014-09-10 | Eisai R&D Man Co Ltd | COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE |
| BR112012018232B8 (pt) | 2010-01-26 | 2023-01-10 | Eisai R&D Man Co Ltd | Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US20120077837A1 (en) | 2010-09-24 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Anti-tumor agent |
| EP2680839A1 (en) * | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| EP2686441B1 (en) | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| JP6021805B2 (ja) * | 2011-04-18 | 2016-11-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| WO2012154935A1 (en) | 2011-05-12 | 2012-11-15 | Eisai R&D Management Co., Ltd. | Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof |
| EP3444363B1 (en) * | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN106029070A (zh) | 2014-03-03 | 2016-10-12 | 卫材R&D管理有限公司 | 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途 |
| AU2015267099B2 (en) | 2014-05-28 | 2020-08-27 | Eisai R&D Management Co., Ltd | Use of eribulin in the treatment of cancer |
| WO2015184145A1 (en) | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| JP6644479B2 (ja) | 2014-06-24 | 2020-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用 |
-
2014
- 2014-06-26 WO PCT/JP2014/067723 patent/WO2014208774A1/en not_active Ceased
- 2014-06-26 EP EP14739971.1A patent/EP3013335B1/en active Active
- 2014-06-26 KR KR1020167001713A patent/KR102265952B1/ko active Active
- 2014-06-26 ES ES14739971T patent/ES2705698T3/es active Active
- 2014-06-26 CA CA2915005A patent/CA2915005C/en active Active
- 2014-06-26 BR BR112015029386-7A patent/BR112015029386B1/pt active IP Right Grant
- 2014-06-26 US US14/315,930 patent/US9549922B2/en active Active
- 2014-06-26 CN CN201480036218.0A patent/CN105338977B/zh active Active
- 2014-06-26 AU AU2014299699A patent/AU2014299699B2/en active Active
- 2014-06-26 RU RU2016102158A patent/RU2672585C2/ru active
- 2014-06-26 JP JP2015562231A patent/JP6404242B2/ja active Active
-
2015
- 2015-11-01 IL IL242386A patent/IL242386B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528162A5 (cg-RX-API-DMAC7.html) | ||
| RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
| JP2014509659A5 (cg-RX-API-DMAC7.html) | ||
| JP2014512356A5 (cg-RX-API-DMAC7.html) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2014512354A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512398A5 (cg-RX-API-DMAC7.html) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| RU2015126661A (ru) | Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| CN104436194A (zh) | 具有协同增效作用的抗癌组合物 | |
| RU2016136504A (ru) | ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ | |
| JP2017526695A5 (cg-RX-API-DMAC7.html) | ||
| JP2017507151A5 (cg-RX-API-DMAC7.html) | ||
| JP2015527374A5 (cg-RX-API-DMAC7.html) | ||
| JP2009536956A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530181A5 (cg-RX-API-DMAC7.html) | ||
| JP2021105005A5 (cg-RX-API-DMAC7.html) | ||
| JP2015507020A5 (cg-RX-API-DMAC7.html) | ||
| CN105283456B (zh) | 5-溴-靛玉红 | |
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
| RU2014104993A (ru) | Кристаллическая форма натриевой соли 4-трет-бутил-n-{4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил}-бензолсульфонамид | |
| JP2021505669A5 (cg-RX-API-DMAC7.html) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами |